 |
|
|
| |
Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir
in Patients With Signs of Portal Hypertension
|
| |
| |
EASL 2021 Presented at The International Liver Congress (EASL), 23-26 June 202
RS Brown Jr1, MA Collins2, A Emmett2, A Topp2, M Burroughs2, R Ferreira2, JJ Feld3
1Center for Liver Disease and Transplantation, Weill Cornell Medical College, New York, New York, United States; 2AbbVie Inc., North Chicago, Illinois, United States; 3Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Ontario, Canada
|
| |
|
|
|
|
|
